Navigation Links
Abbott Opens New State-of-the-Art R&D Facility to Help Bring Medicines to Patients Faster

Company Invests $53 Million in New Lake County, Illinois, Pharmaceutical

Development Center

ABBOTT PARK, Ill., June 12 /PRNewswire-FirstCall/ -- Today Abbott (NYSE: ABT) officially opens its new Formulation Development Center at the company's headquarters in Abbott Park, Ill. The new facility provides leading capabilities for the formulation of new investigational medicines that have the potential to treat cancer and other deadly diseases. The center's technology and equipment will help enable Abbott to expedite its development programs, potentially bringing innovative new pharmaceuticals to patients faster.

"The new formulation center is a clear example of Abbott's commitment to advancing scientific innovation," said John Leonard, M.D., senior vice president, Pharmaceuticals, Research and Development, Abbott. "With the growing number of compounds in Abbott's pipeline, the new center utilizes the latest technology to accelerate the development of future medicines."

The Formulation Development Center supports programs for both potent (drugs with highly active ingredients that require special handling) and non-potent oral compounds. This includes state-of-the-art capabilities for the safe formulation of potent compounds, such as cancer therapies, that are increasingly becoming more effective at low-dose levels.

Abbott's new facility is focused on transforming complex molecules from the laboratory into tablets and capsules that can be used in pre-clinical and clinical studies to determine safety and efficacy. Formulation is an important step in the research and development process, providing a crucial link between the laboratory and commercial manufacturing. Formulation and process work begins shortly after a candidate molecule is identified. Initial formulations are then refined as more information is gathered through the development process.

The center was specifically designed with cutting-edge equipment and improvements to advance the R&D process, including automated technologies that reduce the time for preparing, producing and refining pilot drug formulations. In addition, all of the equipment in the facility is aligned with the production equipment in Abbott's commercial manufacturing sites, which will allow for rapid scale-up of production as drug compounds move toward late-stage clinical trials and market availability for patients.

"We considered several locations for the new formulation center, but decided to strategically place the building in the midst of our other Abbott Park R&D facilities to provide easy access for our scientists, pharmacists and engineers," said Leonard.

Fast Facts for Abbott's New Formulation Development Center

-- Location: Abbott Park, Ill.

-- Size and structure: Two-story, 64,000-square-foot facility features a

flexible design with modular walls and ceilings that will allow for

rapid future expansion

-- Key Current Formulation Programs: Currently developing oral

formulations (capsule and tablet) for clinical studies involving new

compounds to treat cancer, hepatitis, pain and other areas

-- Investment: $53 million

-- Facility Initiated/Completed: Groundbreaking in June 2005; Completed in

January 2008

-- Personnel: Seventeen dedicated onsite employees; more than 40

additional staff regularly work in the facility

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has focused on providing comprehensive solutions involving adult stem cell therapies to patients ... officially deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish ... referral for dental implants at her Mississauga, ON practice. Dr. Williams has ... the placement of dental implants. , Missing teeth can lead to a variety ...
(Date:11/24/2015)... FRANCISCO, CA (PRWEB) , ... November 24, 2015 ... ... half-cup sizes, has launched their Black Friday sale a week early, offering 40% ... continues to transform the intimate apparel industry through both mobile fit technology and ...
(Date:11/24/2015)... ... November 24, 2015 , ... DMG Productions announced that they will feature ... quarter 2016 via Discovery Channel. Dates and show times TBA. , Aphria, Inc., is ... the business of producing and supplying medical marijuana pursuant to the Marijuana for Medical ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... November 25, 2015 ... addition of the  "Global Drug Device ... to their offering.  --> ... of the  "Global Drug Device Combination ... their offering.  --> Research ...
(Date:11/24/2015)... 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" or ... R&D capability and technology platform company serving the pharmaceutical, ... China and the United ... general meeting of shareholders held today, the Company,s shareholders ... approve the previously announced agreement and plan of merger ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
Breaking Medicine Technology: